Evidence map›Paper›PMID 23374337›Full record

ReviewCell2013

Gene copy-number alterations: a cost-benefit analysis.

Yun-Chi Tang, Angelika Amon

Open access · bronzeAbstract readReview
In one paragraph

Review in Cell, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 203 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
203citing papers in PubMed, 2 pooled it
22.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

203 citing papers in PubMed, 2 syntheses or guidelines pooled it, 374 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. The genomic origins and evolutionary path to a key innovation in the world's most venomous snakes.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025
    Review
  17. Article
  18. Article
  19. Article
  20. Article

143 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Yun-Chi TangDavid H. Koch Institute for Integrative Cancer Research, Howard Hughes Medical Institute, Massachusetts Institute of Technology, 76-561, 500 Main Street, Cambridge, MA 02139, USA.
Angelika Amon
Howard Hughes Medical Institute · USMassachusetts Institute of Technology · US

Funding

Regulation of Mitosis by Proteolysis in YeastR01GM056800 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI AMON, ANGELIKA B · 2004 to 2015
$3.4M
REGULATION OF MITOSIS BY PROTEOLYSIS IN YEASTR29GM056800 · NIGMS · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI AMON, ANGELIKA B · 1997 to 2003
$738k
Howard Hughes Medical InstituteNIGMS NIH HHS GM56800NIGMS NIH HHS R01 GM056800NIGMS NIH HHS R29 GM056800
6 · The paper itself

Abstract

Changes in DNA copy number, whether confined to specific genes or affecting whole chromosomes, have been identified as causes of diseases and developmental abnormalities and as sources of adaptive potential. Here, we discuss the costs and benefits of DNA copy-number alterations. Changes in DNA copy number are largely detrimental. Amplifications or deletions of specific genes can elicit discrete defects. Large-scale changes in DNA copy number can also cause detrimental phenotypes that are due to the cumulative effects of copy-number alterations of many genes simultaneously. On the other hand, studies in microorganisms show that DNA copy-number alterations can be beneficial, increasing survival under selective pressure. As DNA copy-number alterations underlie many human diseases, we will end with a discussion of gene copy-number changes as therapeutic targets.

Indexed as

AneuploidyDNA Copy Number VariationsPolyploidyAnimalsGene DosageGene ExpressionGenetic FitnessHumansNeoplasmsPlantsYeasts

Identifiers

PMID23374337
PMCPMC3641674
OpenAlexW2011172223

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.